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TRMT5 Mutations Cause a Defect in Post-transcriptional
Modification of Mitochondrial tRNA Associated
with Multiple Respiratory-Chain Deficiencies
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Deficiencies in respiratory-chain complexes lead to a variety of clinical phenotypes resulting from inadequate energy production by the
mitochondrial oxidative phosphorylation system. Defective expression of mtDNA-encoded genes, caused by mutations in either the
mitochondrial or nuclear genome, represents a rapidly growing group of human disorders. By whole-exome sequencing, we identified
two unrelated individuals carrying compound heterozygous variants in TRMT5 (tRNA methyltransferase 5). TRMT5 encodes a mito-
chondrial protein with strong homology to members of the class I-like methyltransferase superfamily. Both affected individuals pre-
sented with lactic acidosis and evidence of multiple mitochondrial respiratory-chain-complex deficiencies in skeletal muscle, although
the clinical presentation of the two affected subjects was remarkably different; one presented in childhood with failure to thrive and
hypertrophic cardiomyopathy, and the other was an adult with a life-long history of exercise intolerance. Mutations in TRMT5 were
associated with the hypomodification of a guanosine residue at position 37 (G37) of mitochondrial tRNA; this hypomodification was
particularly prominent in skeletal muscle. Deficiency of the G37 modification was also detected in human cells subjected to TRMT5
RNAi. The pathogenicity of the detected variants was further confirmed in a heterologous yeastmodel and by the rescue of themolecular
phenotype after re-expression of wild-type TRMT5 cDNA in cells derived from the affected individuals. Our study highlights the impor-
tance of post-transcriptional modification of mitochondrial tRNAs for faithful mitochondrial function.Mitochondria require unique and highly specializedmech-
anisms to maintain and express their genome (mtDNA).
The mitochondrial genome encodes 13 essential subunits
of the mitochondrial oxidative phosphorylation system
(OXPHOS) and a set of tRNAs and rRNAs required for their
translation. All protein components of the mitochondrial
translation apparatus, including the mitochondrial ribo-
somal proteins, translation factors, aminoacyl tRNA syn-
thetases, RNA modifying enzymes, and other auxiliary
factors are encoded by nuclear genes and, after their syn-
thesis in the cytoplasm, are delivered to mitochondria.
Defective mtDNA expression, caused by mutations in
either the mitochondrial or nuclear genomes, is associated
with a diverse group of human disorders characterized by
impaired mitochondrial respiration.1–3
The 22 mitochondrially encoded tRNAs (mt-tRNAs) act
as crucial intermediaries between the mRNAs transcribed
from mtDNA and the 13 subunits of OXPHOS that they
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The Amerundergo numerous post-transcriptional nucleotide modifi-
cations prior to becoming active elements in protein trans-
lation in order to ensure efficiency and stringent accuracy.
Mitochondrial tRNA processing and modifying enzymes
represent an expanding group of mitochondrial disease-
causing factors.4 Recent research describes mitochondrial
dysfunction resulting from mutations in genes encoding
the tRNA processing enzymes HSD10 (also known as
MRPP2 [MIM: 300256])5 and ELAC2 (MIM: 605367),6 as
well as tRNA modifiers, including PUS1 (MIM: 608109),7
TRIT1,8 TRMU (also known as MTU1 [MIM: 610230]),9
TRNT1 (MIM: 612907),10,11 MTO1 (MIM: 614667),12 and
GTPBP3 (MIM: 608536).13 Furthermore, primary mtDNA
mutations in mt-tRNA genes, which are a frequent cause
of human respiratory-chain deficiencies, can also affect
mt-tRNA modification.14–16
The tRNA anticodon loop position 37 (30 of and adjacent
to the anticodon) has risen to prominence with regard to
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Figure 1. TRMT5 Variants and Gene Structure
(A) Pedigrees of the two families identified with recessively inherited TRMT5 variants. ‘‘D’’ indicates anonymous sperm donor.
(B) Gene structure of TRMT5 with known protein domains of the gene product and location and conservation of amino-acid residues
affected bymutations (in red). Intronic regions are not drawn to scale. Shadowing in the sequence alignment represents the homology of
amino-acid residues.all tRNAs, regardless of organism, are modified at this site.
Sophisticated purine modifications are found at position
37 (for example, N6-(dimethylallyl)adenosine, N6-2-meth-
ylthio-N6-threonylcarbamoyladenosine, and methylwyo-
sine),17 demonstrating the critical role for this site. In
Bacteria, N1-methylation of the guanosine at tRNA posi-
tion 37 (m1G37) is performed by TrmD-type enzymes.18
In Archaea and Eukarya, m1G37 is introduced by
evolutionarily and functionally unrelated Trm5-type pro-
teins.19 In the yeast Saccharomyces cerevisiae, Trm5p
is responsible for m1G37 methylation of cytoplasmic
and mitochondrial tRNAs.20,21 The human ortholog,22
TRMT5 (tRNA methyltransferase 5), catalyzes the forma-
tion of m1G37 in vitro. The presence of m1G37 has
been identified in mitochondrial tRNALeu(CUN)23 and
tRNAPro24; however, the involvement of human TRMT5
has yet to be confirmed in vivo. In vitromethylation assays
with human TRMT5 demonstrated low activity by using a
mitochondrial substrate relative to a cytosolic substrate.22320 The American Journal of Human Genetics 97, 319–328, August 6Mitochondrial localization of TRMT5 within human cells
has not been studied.
Subject 73901 (F1, II.3; Figure 1A) had a life-long history
of exercise intolerance with prominent exertional dys-
pnea. A detailed clinical and physiological characterization
of this subject has been reported in the literature.25 She
presented at the age of 25 years with prolonged dyspnea
associated with lactic acidosis following an episode of pro-
longed walking. Subsequent evaluation led to the diag-
nosis of a mitochondrial myopathy associated with a
marked histochemical and biochemical deficiency of cyto-
chrome c oxidase (COX), along with a defect in complex III
activity.25 At the time of this evaluation she predomi-
nantly had exercise intolerance but also had slight gait
unsteadiness and equivocal extensor plantar reflexes. She
was able to perform her duties as a nurse. In her early
30s, she developed signs of exocrine pancreatic failure
and malabsorption. Neurological evaluation at the age of
35 years revealed hyperreflexia and extensor plantar, 2015
Table 1. Genetic and Clinical Findings in Individuals with TRMT5 Variants
ID Sex TRMT5 Variantsa
OXPHOS Activities in Skeletal Muscle Clinical Features
Respiratory-
Chain
Complex
Enzyme
Activity
Absolute
Values
Reference
Range
(Mean 5 SD
[range])
Histo-
chemical
COX
Defect
Age at
Onset
Clinical
Course Other Features
73901b female c.[312_315del;
872G>A],
p.[Ile105Serfs*4;
Arg291His]
I 59% 2.9 4.9 5 0.9
(3.1–6.7)
>95%
COX-
deficient
fibers
childhood died at
55 years
of age
life-long exercise
intolerance, dyspnea,
lactic acidosis, pancreatic
disorder, spasticity/
peripheral neuropathy,
muscular weakness,
renal tubulopathy,
cirrhosis
II 138% 2.9 11.2 5 2.7
(5.8 16.6)
IIþIII 47% 5.3 2.1 5 0.6
(0.9–3.4)
IV 36% 1.4 3.9 5 1.3
(1.3–6.6)
65205c male c.[312_315del;
1156A>G],
p.[Ile105Serfs*4;
Met386Val]
I 32% 88 272 5 115
(84–559)
none birth alive,
7 years old
premature delivery, failure
to thrive, growth
retardation, intestinal
pseudo-obstruction,
hypertrophic non-
obstructive
cardiomyopathy, muscular
hypotonia, demyelinating
neuropathy, global
developmental delay,
lactic acidosis
II ND ND ND
IIþIII 136% 154 1105 70
(37–285)
IV 27% 315 1150 5 400
(520–2080)
Abbreviation is as follows: ND, no data.
acDNA (GenBank: NM_020810.3), protein (GenBank: NP_065861.3).
bFor subject 73901, enzyme activities are expressed as percentage of control enzyme activity. Absolute values of residual enzyme activities are expressed as
U/min/g wet weight, and the reference range (mean 5 SD [range]) is shown for 46 control subjects.
cFor subject 65205, percentages of residual enzyme activities are normalized to citrate synthase activity. Absolute values are expressed as mU/U citrate synthase
activity, and the reference range is shown for 52 (complex I) and 27 (complex IIþIII and IV) control subjects.reflexes with some clinical spasticity, as well as mild
distally reduced pallesthesia. When evaluated at the age
of 40 years, she reported prominent dyspnea with trivial
exercise and felt somewhat short of breath much of the
time. She had developed weakness and difficulty getting
up from low chairs or climbing steps unless there was a
handrail, and she could not get up from the floor without
help. Her pancreatic disorder worsened. There was an
apparent renal tubular defect with 4þ glycosuria despite
normal blood glucose levels. She developed glucose intol-
erance with an HbA1c concentration as high as 7.5%
(normal< 5.7%) and began experiencing nausea and vom-
iting two to three times a month. She had no symptoms of
sensory loss and her cognitive function was normal. An
abdominal computed tomography scan at the age of 53
years showed cirrhosis, and she began developing ascites,
hence she was evaluated for a possible liver transplant.
She had increasing weakness, especially in her legs, and
difficulty standing. However, neck weakness was absent
and she had neither difficulty chewing or swallowing nor
dysarthria. There was no known cardiac involvement apart
from tachycardia during minor exercise.25 A more recent
muscle biopsy revealed a severe histochemical defect of
COX (Figure S1) and decreased activities of respiratory
complexes I, III, and IV (Table 1), whereas fibroblast studies
showed normal activities. Interestingly, serum FGF21
levels determined at the time of biopsy were markedly
increased (2,851 pg/ml; mean 5 SD [and normal range]The Amerfor healthy subjects ¼ 175 5 155 pg/ml, range ¼ 58–569
pg/ml, n ¼ 10). She died during her sleep at the age of
55. There was no family history of mitochondrial disease.
She has three brothers and two sisters, who are all healthy.
Both parents are deceased (Figure 1A).
Subject 65205 (F2, II.1; Figure 1A,), is the only child of a
healthy mother of northern European descent and an
anonymous sperm donor; the family history is empty.
Pregnancy was complicated by placental insufficiency
and incipient preeclampsia. At 35 weeks and 4 days of
gestation, he was born small for date (Z score for weight
was 2.2). In the first month of life, he showed irritability,
tremor, high-pitched cries, muscular hypertonia, feeding
difficulties, and inadequate weight gain. At the age of
3 months, a delayed psychomotor development was
noted. At the age of 6 months, follow-up of tachycardia
revealed a hypertrophic non-obstructive cardiomyopathy
(HNOCM). Furthermore, he showed slight dystrophy
and dysmorphic signs (asymmetric plagiocephalus, trian-
gular face with small mouth, blue sclerae, unilateral
maxillary fused primary incisor, and unilateral partial syn-
dactyly of toes two and three). Chromosome anomalies
including del22q11.2 and Pompe disease were excluded.
Selective metabolic screening showed slightly elevated
lactate in blood and urine. Brain MRI at 9 months of age
showed slight brain atrophy, a larger left hemisphere,
and delayed myelination. Brain magnetic resonance spec-
troscopy showed normal values without a lactate peak.ican Journal of Human Genetics 97, 319–328, August 6, 2015 321
Given that marked hyporeflexia and delayed nerve con-
duction were evident, Krabbe disease and metachromatic
leukodystrophy were excluded. A persistent mild hypercal-
cemia was noted. At 17 months of age, a norovirus
infection led to decompensation of the HNOCM and a
nasogastric tube feeding was required. Moderate elevation
of serum lactate (3.3–5.7 mmol/l, rising to 9.2 mmol/l on
another occasion; normal range ¼ 0.7–2.1 mmol/l) was
noted; furthermore, alanine, threonine, and glycine levels
were elevated. Elevation of cerebrospinal fluid lactate and
alanine was also noted; serum FGF21 levels were not deter-
mined. Histological examination of a muscle biopsy
showed slight myopathic changes and lipid droplets but
no ragged-red fibers. Electron microscopy showed normal
mitochondrial morphology and no further abnormalities.
Respiratory-chain analysis in frozen muscle tissue showed
decreased activity of respiratory complex IV and border-
line-low complex I activity (Table 1), whereas fibroblast
studies showed normal values. Consequently, mitochon-
drial disease was confirmed, and a treatment with coen-
zyme Q10, creatine, thiamine, and ascorbic acid was
initiated. Considerable tympanites and gastro-intestinal
dysmotility with frequent vomiting were evident. A gastro-
stomy tubewas placed at 2 years of age. Currently, at 7 years
of age, he remains a cheerful boy with a moderate to severe
developmental delay. Presenting with muscular hypotonia
and hypermotoric activity, he moves around in a wheel-
chair or by rolling on the ground and is unable to sit, stand,
or walk unsupported. He communicates by facial expres-
sions, gestures, and sounds. There is no visual or hearing
impairment. Growth impairment is reflected by low body
weight (Z score is 3.8), length (Z score is 3.1), and
head circumference (Z score is 3.6). Bone age is delayed
by 2.5–4 years. The HNOCM is stable, showing hypertro-
phy of the left ventricle (Z score for the interventricular
septum-wall diameter is þ6.7, Z score for the posterior
left ventricular-wall diameter is þ8.0) and fractional
shortening of 33%. His current medication comprises co-
enzyme Q10, thiamine, riboflavin, omeprazole, and dom-
peridone. He is showing minor developmental progress
from receiving physiotherapy and occupational and
speech therapy and being supported by adaptive devices.
Informed consent for diagnostic and research studies was
obtained for both subjects in accordance with the Declara-
tion of Helsinki protocols and approved by local institu-
tional review boards.
Having excluded mtDNA copy-number depletion by
qPCR,26,27 mtDNA rearrangements by long-range PCR28
and mtDNA point mutations by direct Sanger se-
quencing29 in both subjects, we proceeded to undertake
whole-exome sequencing (WES) to elucidate themolecular
basis of the disease in individuals 73901 and 65205 by
using previously described methodologies and bio-
informatic filtering pipelines2,8,30,31 from which both
affected individuals were found to harbor variants in
TRMT5. Subject 73901 harbored compound heterozygous
TRMT5 variants (GenBank: NM_020810.3): a c.312_322 The American Journal of Human Genetics 97, 319–328, August 6315del (p.Ile105Serfs*4) frameshift and a c.872G>A
(p.Arg291His) missense variant. Both were confirmed by
Sanger sequencing in the affected individual, and all
five healthy siblings are heterozygous carriers of the
c.872G>A (p. Arg291His) variant; parental samples were
not available for carrier testing (Figure 1A). Subject 65205
harbored two heterozygous TRMT5 variants: the same
c.312_315 del (p.Ile105Serfs*4) frameshift variant identi-
fied in individual 73901 and a c.1156A>G (p.Met386Val)
missense variant. The presence of both variants was
confirmed by Sanger sequencing. Carrier testing confirmed
heterozygosity of the p.Met386Val variant in the mother.
No material from the father was available for testing. The
p.Arg291 and p.Met386 residues show absolute evolu-
tionary conservation between human and yeast (Fig-
ure 1B). None of the identified variants are present in our
combined exome database, which contains > 5,700 sam-
ples. In the Exome Aggregation Consortium (ExAC)
Browser, we found two of the three variants. The
c.312_315del variant is reported with a minor-allele fre-
quency (MAF) of 0.0009 (112/121,378 alleles), whereas
the c.872G>A variant was detected five times (MAF ¼
0.00004). Both missense changes are predicted to be dele-
terious according to PolyPhen-2 (p.Arg291His, probably
damaging, score ¼ 1.000 and p.Met386Val, probably
damaging, score ¼ 0.992) and SIFT (p.Arg291His, affects
protein function, score ¼ 0.00 and p.Met386Val, affects
protein function, score ¼ 0.00).
The p.Ile105Serfs*4 frameshift mutation is upstream of
the methyltransferase motif (Figure 1B), predicting a trun-
cated protein that is expected to be non-functional. In
order to evaluate the consequences of p.Arg291His and
p.Met386Val variants on the enzyme function, we gener-
ated a homology model for TRMT5 by using SWISS-
MODEL (Figure 2 and Figure S2A). For the modeling of
the TRMT5 fragment corresponding to the SAM-depen-
dent methyltransferase domain (residues 193–470, SCOP:
53335), we used the structure of the corresponding
domain from the homologous Methanocaldococcus janna-
schii aTrm5 (residues 92–334, PDB: 2NNZ) as a template.
Recent research has shown that human TRMT5 is an active
methyltransferase and that it is generally similar to aTrm5
in catalysis.33 Arg291 is in close vicinity to the strictly
conserved and catalytically critical Glu288. Substitution
of Glu288 in the human enzyme reduces the reaction
rate by over 300-fold.33 It has been proposed that Glu288
participates in an acid-base proton-transfer reaction from
the N1 of G37.32 The structural analysis performed here in-
dicates that Arg291 forms two hydrogen bonds with
Glu288 (Figure S2B). Substitution of Arg291 is expected
to affect the interaction with Glu288, destabilizing the
active-site structure. The Met386 residue is adjacent to
Asn387. Asn387 forms hydrogen bonds with G37 and
SAM, bringing them in close proximity to each other and
allowing the catalysis of N1-methylation.32 Although
Met386 is not directly involved in catalysis, its substitution
to a small aliphatic amino acid is predicted to affect the, 2015
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Figure 2. 3D Model of Human TRMT5
(A) Ribbon presentation of theMethanocaldococcus jannaschii aTrm5–tRNACys(GCA)–AdoMet complex structure. The fragment of structure
typical for the AdoMet-dependent methyltransferases superfamily (SCOP: SSF53335) is colored gray (the remaining portion of aTrm5 is
colored cyan). tRNACys is colored light orange, and G37 is presented as a stick model. SAM are depicted as stick models and carbon atoms
are yellow. The residues that are key for catalysis32 are indicated in green.
(B) Detailed view of the structural model of the catalytic site of aTrm5. Color coding is the same as in panel (A).
(C) Detailed view of the 3D model of the predicted catalytic site of human TRMT5. TRMT5 residues corresponding to the catalytically
important amino acids in aTrm5 are indicated in dark green. Seven out of nine catalytically important residues are absolutely conserved
in TRMT5 and aTrm5, and the remaining two, His289 (Methanocaldococcus jannaschii Arg186) and Arg454 (Methanocaldococcus jannaschii
Lys318), share very similar chemical properties between the two proteins. The residues mutated in individuals 73901 and 65205, Arg291
and Met389, respectively, are indicated in red.structure of the catalytic pocket by altering the position of
Asn387 and preventing proper hydrogen-bond formation.
In conclusion, homology modeling implies that presence
of the Met386Val and Arg291His variants would interfere
with catalysis of TRMT5.
The subcellular localization of TRMT5 has not been stud-
ied thus far. Given the mitochondrial respiratory-chain
deficiencies detected in individuals with potentially path-
ogenic TRMT5 variants, we set out to determine whether
TRMT5 is a mitochondrial protein. Mitochondrial localiza-
tion of TRMT5 was analyzed immunocytochemically with
a FLAG-tagged version of the protein (TRMT5-FLAG,
mRNA [GenBank: NM_020810.3] coding for a 509-aa pro-
tein). The corresponding cDNA was transiently expressed
in HeLa cells as described previously.34 Signals from an
anti-FLAG antibody and an antibody targeted against the
mitochondrial protein TOM20 were shown to co-localize
(Figure 3A). Cellular fractionation experiments, performed
as described previously,35 with HeLa cells indicated that
the endogenous TRMT5 is enriched within the mitochon-
drial fraction, along with a known mitochondrial matrix
protein, mtSSB1. Both TRMT5 and mtSSB1 were resistant
to proteinase K treatment of the mitochondrial fraction,
whereas in similar conditions the outer-membrane protein
TOM22 was truncated by proteinase K digestion (Fig-
ure 3B), confirming that TRMT5 is localized within mito-
chondria in human cells.
Next we intended to determine whether the identified
TRMT5 variants result in diminished G37 modification of
a mitochondrial tRNA. The detection of N1-methylguano-
sine by reverse-transcription primer extension (RT-PEx)
makes use of the modification’s ability to interfere withThe Amerstandard Watson-Crick base pairing, thereby causing the
reverse transcriptase to pause when incorporating cytosine
and preventing the extension reaction from proceeding
past themodification site (Figure S3). Reverse-transcription
reactions were performed in the absence of a particular
dinucleotide triphosphate (dNTP) selected to cause reac-
tion stalling shortly downstream from the modification
site, in our case deoxythymidine triphosphate (dTTP) for
mitochondrial tRNALeu(CUN) (Figure 4A). The ratio between
these two extension products is therefore proportional to
the abundance of the modification (Figure S3). On the
basis of previously published data reporting the presence
of m1G37 in mitochondrial tRNALeu(CUN)23, a suitable
primer was designed to anneal to this mt-tRNA (Figure 4A).
This primer was subject to radioactive labeling and used in
the RT-PEx assay using total RNA extracted from primary
skin fibroblasts, as described previously.34 RT-PEx reactions
performed in control cell lines demonstrate that only a
small percentage (~5%) of primers are able to readthrough
G37, indicating high modification levels in the mt-
tRNALeu(CUN) in control cells. This high activity of
TRMT5 on its substrate is consistent with the previously
described essential role of m1G37. However, mt-
tRNALeu(CUN) was found to have considerably decreased
levels of the m1G37 modification in primary fibroblasts
from both individuals, as demonstrated by increased read-
through past G37 (Figure 4B). The loss of m1G37 does not
appear to impact tRNA stability, given that similar steady-
state levels of mt-tRNALeu(CUN) are found in control and
affected fibroblast cells (Figure S4A). Remarkable tissue
specificity for the effect of TRMT5 variants on G37 modifi-
cation was identified when mt-tRNA from skeletal muscleican Journal of Human Genetics 97, 319–328, August 6, 2015 323
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Figure 3. Mitochondrial Localization of
TRMT5
(A) Localization of TRMT5 by immunoflu-
orescence in HeLa cells following the tran-
sient expression of a C-terminal FLAG-
tagged TRMT5 construct (TRMT5-FLAG).
Cell nuclei were stained with DAPI (top
left). TRMT5-FLAG was detected by an
anti-FLAG antibody (top right). We de-
tected mitochondria by targeting a known
mitochondrial protein, TOM20, with an
anti-TOM20 antibody (bottom left). We
digitally merged the preceding images,
and signal overlap between TRMT5-FLAG
and TOM20 appears yellow (bottom right).
(B) Localization of TRMT5 in sub-cellular
fractions. HeLa cells were fractionated
into debris (D, lane 2), cytosol (C, lane 3),
and mitochondria (C, lanes 4–6). The
mitochondrial fraction was treated with
25 mg/ml proteinase K in the absence (C,
lane 5) or presence (C, lane 6) of 1% Triton
X-100. The fractions were analyzed by western blotting with antibodies against TRMT5 (HPA000943, Sigma). The distribution of TRMT5
was compared with that of the following marker proteins: mtSSB1 (mitochondrial matrix), TOM22 (mitochondrial outer membrane),
GAPDH (cytosol), and Histone H4 (nucleus). Abbreviations are as follows: T, total cell lysate; fl, full-length TOM22; tr, truncated TOM22.was analyzed in the same assay (Figure 4C). RT-PEx reac-
tions performed on total RNA preparations isolated from
skeletal-muscle biopsy samples of affected individuals
demonstrated severely diminished pausing at G37, in
particular for the 65205 sample as compared to the control
samples (Figure 4C).
In order to further corroborate a direct role of TRMT5 in
mt-tRNA modification, we downregulated its amount by
using RNA interference in HeLa cells (Figure 4D)36 and
confirmed the reduction of TRMT5 amounts by western
blotting (Figure S4B). The siRNA-mediated depletion of
TRMT5 resulted in G37 hypomodification in mt-
tRNALeu(CUN) in the RT-PEx assay, as observed for the sam-
ples derived from the affected individuals (Figure 4D).
Taken together, our results thus far establish TRMT5 as
the methyltransferase responsible for m1G37 modification
in human mitochondrial tRNAs and suggest the variants
detected in subjects 65205 and 73901 as responsible for
their respiratory-chain abnormalities.
In order to confirm that defects in TRMT5 are the cause
of the aberrant modification of G37 in mt-tRNALeu(CUN),
we transduced the 65205, 73901, and control primary fi-
broblasts with a wild-type copy of TRMT5 cDNA by using
a lentiviral vector (pLenti 6.3/V5 TOPO, Life Technologies)
as previously described.37 The transduction had no notice-
able effect on the G37 modification status of mt-
tRNALeu(CUN) in the control-cell line (C2-T, Figure 5A).
However, in transduced 73901 fibroblasts, the expression
of wild-type TRMT5 was found to reverse the hypomodifi-
cation effect observed in fibroblasts from the affected indi-
viduals, resulting in m1G37 amounts matching those of
the control individual (73901-T, Figure 5A). We were un-
able to recover any viable cells from subject 65205 after
the transduction procedure.
To further substantiate the pathogenicity of the
identified TRMT5 variants, we utilized a yeast model324 The American Journal of Human Genetics 97, 319–328, August 6to analyze the Trm5p p.Arg270His and p.Met396Val sub-
stitutions corresponding to the human p.Arg291His and
p.Met386Val variants, respectively (Figure 1B). In yeast,
Trm5p has a dual, cytoplasmic and mitochondrial localiza-
tion; consequently, the null mutant is lethal. The strain
that lacks the Trm5p mitochondrial targeting sequence
(amino acids 1–33) fails to localize Trm5p to themitochon-
dria, resulting in a respiratory deficiency.21 To obtain the
‘‘null mitochondrial’’ mutant, we constructed a gene en-
coding a protein lacking amino acids 1–33 (D1–33). This
mutant displayed a 20% reduction of respiratory activity.
In order to accentuate this effect, we expressed trm5D1-
33 in a ParR strain that exhibits destabilized mt-tRNA-
mitoribosome interaction, as a result of paromomycin-
resistant mutation in its mitochondrial 15S rRNA gene,
which renders the 15S RNA site A structurally similar to
the human 12S RNA site A.12 In this genetic background,
the trm5D1-33 mutant showed ~40% reduction of respira-
tory activity (Figure 5B). The respiratory phenotype was
rescued by expression of a wild-type copy of TRM5
(Figure 5B). However, expression of alleles carrying either
the trm5R270H or the trm5M396V mutation did not lead to
a full recovery of the decreased mitochondrial respiratory
activity (Figure 5B). In conclusion, these data confirm a
causal role for the p.Arg291His and p.Met386Val TRMT5
variants in the mt-tRNA modification and oxidative meta-
bolism deficiency in the reported individuals.
Our experiments have shown that TRMT5 is responsible
for the m1G37 modification in human mitochondrial
tRNA molecules. Position 37 of a tRNA is almost exclu-
sively a purine, and the G or A is modified to m1G or i6A
in most cases. Both of these modifications have been
shown to significantly enhance translational efficiency
and accuracy in yeast, and the loss of i6A has been recently
linked to pathogenicity in individuals with severe
combined mitochondrial respiratory-chain defects.8 The, 2015
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Figure 4. Hypomodification of G37 in Mitochondrial tRNA
in Affected Individuals and upon Downregulation of TRMT5
Expression
(A) A radioactively labeled, complementary primer (red) is an-
nealed to mt-tRNALeu(CUN) and subjected to a RT-PEx reaction.
The presence of m1G37 results in RT-PEx pausing, producing a
shorter product (dark blue). However, in the absence of m1G37,
the extension is able to progress until stalling due to the lack of
a dNTP (dTTP in the above case, light blue), producing a longer
product.
(B) Separation and detection of products of RT-PEx reactions pre-
formed on RNA extracted from skin fibroblasts (FB) of healthy con-
trols (C1 and C2) and the affected individuals (65205 and 73901;
left panel). The gel shows a representative result of at least
three biological replicates (right panel). Quantification values
represent percentage of RT-PEx reaction readthrough the G37
site as the average of the dTTP-induced stalling intensity to the
total stalling (dTTP-induced stalling þ m1G37-induced stalling).
Error bars ¼ 1 SEM; n ¼ 5, *p < 0.05, ***p < 0.001, unpaired
two-tailed Student’s t test with C1.
(C) RT-PEx experiment performed as in (B) on RNA extracted from
skeletal muscle (SKM) of healthy control individuals (C1 and C2)
The Amermethylation of G37 to form m1G acts to sterically block
Watson-Crick base pairing and thereby both maintain an
open loop conformation, by blocking base pairing with
nucleotides elsewhere in the anticodon loop, and protect
against frame shifting by preventing its interaction with
the mRNA. The absence of m1G has been shown to lead
to an increase in þ1 frameshifting,38 altering the subse-
quent protein sequence and commonly resulting in a trun-
cated product upon encountering a stop codon. The loss of
m1G37 has also been linked to a reduced stringency of ami-
noacyl-tRNA selection at the ribosome,39 a reduced rate of
polypeptide elongation,40 and an increase in the misacyla-
tion of the tRNA.41 Furthermore, studies of the TRMT5
orthologs in Saccharomyces cerevisiae21 and Trypanosoma
brucei42 have revealed that the protein is responsible for
introducing m1G37 in mt-tRNA and that it plays an essen-
tial role in mitochondrial protein synthesis. Our data
support an analogous activity of TRMT5 in human mito-
chondria given that we identified a reduced modification
of G37 in mt-tRNALeu in both cell lines with TRMT5 vari-
ants and in cells with RNAi-mediated downregulation of
TRMT5 expression. Methylation of G37 has also been de-
tected in mt-tRNAPro26. However, in our RT-PEx experi-
ments, no changes in the mt-tRNAPro G37 modification
were detected in fibroblasts from the analyzed subjects
(Figure S5). This result indicates that either TRMT5 is not
responsible for m1G37 in human mt-tRNAPro, or the
p.Arg291His and p.Met386Val variants affect the enzy-
matic activity in a tRNA-specific manner and with a greater
effect on mt-tRNALeu(CUN). Further studies would be
required to address whether m1G37 is involved either in
maintaining the proper ribosomal reading frame or in
mitochondrial tRNA aminoacylation.
The two reported subjects both presented with lactic
acidosis and evidence of multiple mitochondrial respi-
ratory-chain-complex deficiencies in skeletal muscle,
although the clinical presentation was remarkably dif-
ferent. The female individual (73901) presented mainly
with a history of life-long exercise intolerance with no car-
diac involvement, whereas the male individual (65205)
presented with dysmorphic signs, failure to thrive, growth
retardation, hypertrophic non-obstructive cardiomyopa-
thy, peripheral neuropathy, and moderate to severe
developmental delay in childhood. Interestingly, clinically
relevant MTO1 or GTPBP3 variants responsible for a
different modification in the mt-tRNA anticodon loop (po-
sition 34, ‘‘wobble base’’) have also been associated with
lactic acidosis, multiple respiratory-chain deficiencies,
and hypertrophic cardiomyopathy.12,13 The presence ofand affected individuals (65205 and 73901). Error bars ¼ 1 SEM;
n ¼ 3, ***p < 0.001, unpaired two-tailed Student’s t test with C1.
(D) Separation and detection of RT-PEx reactions on HeLa cells-
derived RNA following a 6-day siRNA-mediated depletion of
TRMT5. Two different siRNA were used (HSS126475 and
HSS126476, Life Technologies). Untransfected cells and cells
transfected with siRNA against GFP (Dsc-1001, Lonza) were used
as controls. Quantification values displayed as per (B).
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Figure 5. Causal Role for p.Arg291His and p.Met386Val TRMT5
Variants in mt-tRNA Modification and Oxidative Metabolism
Deficiency
(A) RT-PEx assay performed on RNAderived from individual 73901
and control (C2) skin fibroblasts (FB) with and without the expres-
sion of wild-type TRMT5. Quantification values are displayed as
per Figure 4B. Error bars ¼ 1 SEM; n ¼ 4, **p < 0.01, unpaired
two-tailed Student’s t test.
(B) Complementation assays in yeast. TRM5 was cloned under its
natural promoter upon PCR amplification. PCR-based mutagen-
esis was performed to obtain the trm5R270H and trm5M368V mutant
alleles. The trm5D1-33 allele was constructed as previously
described.21 Disruption of genomic TRM5 gene was performed in
the presence of TRM5 on the pFL38 plasmid, given that the dele-
tion is lethal. The TRM5, trm5R270H, trm5M368V, and trm5D1-33 alleles
cloned into the pFL39 vector were introduced into this strain, and
then pFL38-TRM5 was lost through plasmid shuffling. Oxygen
consumption rate was recorded on intact cells grown at 28C in
synthetic complete medium without tryptophan, supplemented
with 0.5% glucose. Values were normalized to the rate of oxygen
consumption of the TRM5 transformant and represented as the
mean of at least three values. Error bars ¼ 1 SD; *p < 0.05, paired
Student’s t test.hypertrophic cardiomyopathy as a prominent and com-
mon phenotype in all three disorders indicates tissue-spe-
cific threshold effects; the heart is specifically vulnerable
for a diminished mitochondrial translation rate. The
increased sensitivity of cardiac tissue as a consequence of
a perturbed mitochondrial translation has recently been
recapitulated in an MTO1 mouse model.43,44 It is possible
that the higher degree of mt-tRNA hypomodification de-
tected in individual 65205 (Figure 4) and the consequent
impairment of mitochondrial translation accounts for
the more severe symptoms in this case (Table 1). The latter
is also supported by a modestly lowered respiration rate in
the 65205 fibroblast (Figure S6), but no detectable changes326 The American Journal of Human Genetics 97, 319–328, August 6in oxygen consumption in the 73901 fibroblast. Such non-
overlapping phenotypes between individuals harboring
variants in the same gene involved in mt-tRNAmaturation
have been previously reported.45 The spectrum of clinical
phenotypes associated with mt-tRNA modification defi-
ciencies, including cases without cardiac disorder,9 is
constantly growing.
In summary, through the identification of two individ-
uals with mitochondrial disease-bearing compound het-
erozygous variants in TRMT5, our research further expands
the list of mitochondrial-tRNA-modifying enzymes vital
for proper mitochondrial function. Methylation of gua-
nine 37 in mt-tRNALeu(CUN) is diminished in fibroblasts
and skeletal muscle of affected individuals and recapitu-
lated by siRNA-induced depletion of TRMT5 in HeLa cells,
consistent with mitochondrial localization of the protein.
The involvement of TRMT5 in m1G formation and mito-
chondrial respiratory function was confirmed through
the rescue of tRNALeu(CUN) m1G37 modification by
complementation with wild-type TRMT5 in human fibro-
blasts and by validation of the pathogenic variants in a
yeast model. Given that 7% of all mammalian mt-tRNA
residues undergo post-transcriptional modification, and
that over 30 different modified mt-tRNA positions have
been so far described,46 it is anticipated that future exome
sequencing analyses of individuals with clinically diag-
nosedmitochondrial disease will reveal further pathogenic
variants within mt-tRNA modifying factors.Supplemental Data
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